March 16, 2017 Columns by admin After Long Wait, Zinbryta Gains Approval in Areas of the UK News that daclizumab, brand name Zinbryta, has been given the go-aheadĀ to be available through the U.K.ās National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken…
October 5, 2016 News by Patricia Silva, PhD MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales The Multiple Sclerosis (MS) Trust isĀ expressing its disappointment at the recent committee decision ofĀ theĀ National Institute for Health and Care ExcellenceĀ (NICE)Ā to not recommendĀ Zinbryta (daclizumab) be made available as a therapy to MSĀ patients using the public health system in England and Wales. NICE’sĀ preliminary recommendationĀ was based on a review of…
October 4, 2016 News by Patricia Silva, PhD NICE Planning to Reject MS Treatment, Zinbryta, in England and Wales TheĀ National Institute for Health and Care Excellence (NICE), the health authorityĀ for England and Wales,Ā has decided not to recommend Zinbryta (daclizumab)Ā be made available to multiple sclerosis (MS)Ā patients through the country’s health service. The decision came in a first stage of the drugās review process, and NICE is welcoming…
January 14, 2015 News by Patricia Silva, PhD Plegridy for Relapsing MS Now Approved in Scotland The Scottish Medicines Consortium has just approved Biogen Idec’sĀ Plegridy (peg interferonĀ beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…
November 19, 2014 News by Isaura Santos ‘Treat Me Right’ MS Society Campaign Shortlisted For Award TheĀ Treat Me RightĀ campaign from the MSĀ SocietyĀ in the UK was recentlyĀ shortlistedĀ for this year’s voluntary sector campaignĀ Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…
October 8, 2014 News by Patricia Silva, PhD NICE Releases New Guidance on Multiple Sclerosis Care The British National Institute for Health and Care Excellence (NICE) updated their guidelines on the provision of health care for multiple sclerosis (MS) patients in the United Kingdom, which number approximately 100,000 people. The institute recommends now that every patient who is suspected to suffer from the…
July 22, 2014 News by Patricia Silva, PhD NICE Turns Back and Approves Biogenās Oral MS Drug Tecfidera in the UK The UK’s National Institute for Health and Care Excellence (NICE) gave a positive final appraisal determination to the use of the Biogen Idec‘s drugĀ Tecfidera (dimethyl fumarate) in adults for the treatment of relapsing-remitting multiple sclerosis (RRMS), having turned back on their preliminary negative recommendation. TheĀ oral…